Cargando…
5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report
BACKGROUND: The loss of CD20 protein expression after a rituximab-containing regimen is one of the resistance mechanisms in non-Hodgkin's lymphoma. Recently, it was reported that 5-azacitidine administration upregulates the expression of CD20 in CD20-negative B-cell acute lymphoblastic leukemia...
Autores principales: | Tsutsumi, Yutaka, Ohigashi, Hiroyuki, Ito, Shinichi, Shiratori, Souichi, Teshima, Takanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739428/ https://www.ncbi.nlm.nih.gov/pubmed/26838941 http://dx.doi.org/10.1186/s13256-016-0809-7 |
Ejemplares similares
-
COVID‑19 antibody production by vaccination in chemotherapy with CD20 antibody for B‑cell lymphoma
por: Tsutsumi, Yutaka, et al.
Publicado: (2023) -
Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection
por: Tsutsumi, Yutaka, et al.
Publicado: (2023) -
Evaluation of Short-Term Ruxolitinib Tapering Strategy Before Allogeneic Stem Cell Transplantation for Primary Myelofibrosis Through the Transition of Serum Cytokines and Growth Factors
por: Shiratori, Souichi, et al.
Publicado: (2016) -
Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
por: Serra-Peinado, Carla, et al.
Publicado: (2019) -
Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases
por: Tsutsumi, Yutaka, et al.
Publicado: (2021)